lsif-logo-default (1).png
Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing
March 29, 2021 08:35 ET | Life Sciences Investor Forum
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the March 25th conference are now available for on-demand viewing at...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
March 19, 2021 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
lsif-logo-default (1).png
Virtual Conference for Life Sciences Companies Broadcast Live March 25th, 2021
March 19, 2021 08:35 ET | Life Sciences Investor Forum
NEW YORK , March 19, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals...
BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
March 16, 2021 08:30 ET | BrightInsight
SAN JOSE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global regulated digital health platform for biopharma and medtech, announced today the launch of...
FStar.jpg
F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021
March 16, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Taconic Biosciences Models for Life
Taconic Biosciences Expands Scientific Advisory Board
March 15, 2021 09:00 ET | Taconic Biosciences
RENSSELAER, N.Y., March 15, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its...
Cellectis Logo.png
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
March 04, 2021 16:42 ET | Cellectis Inc.
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical...
abcam-grey.png
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
March 04, 2021 04:00 ET | Abcam
Scaling up R&D, manufacturing and commercial capabilities in Shanghai and Hangzhou Investing in state-of-the-art facilities and equipment to support research, diagnostic and clinical applications ...
Arbutus Biopharma Logo
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
February 12, 2021 19:41 ET | G1 Therapeutics
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - -...